Issuer:
Gilles R. Gagnon
President & CEO
+1 (780) 421-4555
E: ggagnon@ceapro.com Read More
Financial Personal
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: C
